Additionally, our results demonstrated an increased efficacy of anti-PD-1/PD-L1 inhibitors in patients with multiple types of cancer, but the results were not reliable in patients with other types of cancer, possibly owing to the vast size differences between lung cancer and other cancer types. The gene discussed is CD274; the disease is lung carcinoma.